查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011533

人类微生物组市场：按类型、部位、应用和最终用户划分－2026-2032年全球市场预测

Human Microbiome Market by Type, Target Microbiome Site, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人类微生物组市场价值将达到 24.1 亿美元，到 2026 年将成长到 29.8 亿美元，到 2032 年将达到 114 亿美元，年复合成长率为 24.83%。

主要市场统计数据
基准年 2025 24.1亿美元
预计年份：2026年 29.8亿美元
预测年份 2032 114亿美元
复合年增长率 (%) 24.83%

这篇全面的介绍重点阐述了人类微生物组的基本作用、历史演变和战略重要性，揭示了其整体情况。

人类微生物组已迅速从昙花一现的科学兴趣发展成为理解人类健康、疾病预防和治疗方法创新的基础要素。这本全面的导论详细说明了栖息表人体内外的复杂微生物群落如何影响免疫调节、代谢调控和神经路径。透过说明微生物组检验的突破性发现和关键里程碑，读者将了解从早期培养为基础的研究到高通量定序和多体学整合的历程。

透过技术突破、政策进步和策略合作，找出能够彻底改变人类微生物组格局的变革性变化。

人类微生物组的快速演变的核心在于最尖端科技、政策改革和新型合作模式所驱动的变革性变化。定序技术的最新进展，包括新世代定序平台和携带式照护现场设备，正在显着降低时间和成本，实现即时微生物分析，并促进分散式诊断。

评估 2025 年美国贸易关税对人类微生物组领域供应链、成本结构和创新动态的累积影响。

美国将于2025年实施贸易关税​​，这为人类微生物组领域带来了复杂的挑战和战略考量。对关键投入品（例如特殊试剂、高精度定序设备和聚合酵素链锁反应(PCR) 组件）征收的进口关税，正推高诊断设备和实验室耗材的生产成本。这些成本上涨迫使製造商重组供应链，并探索在地采购和近岸外包策略，以降低关税波动带来的风险。

透过按类型、目标微生物组部位、应用和最终用户进行关键市场細項分析，我们揭示了多样化的市场动态。

对市场区隔的深入理解，能够帮助我们洞悉整个人类微生物组价值链中成长机会与竞争压力交会之处。按产品类型划分，市场涵盖了抗生素（其在调节微生物群落方面持续发挥关键作用）以及各种诊断仪器，例如高通量微生物定序平台和基于PCR的快速检测方法。同时，以菊糖和寡糖为中心的益生元领域，凸显了靶向基材在滋养有益微生物方面的重要性；而益生菌和合合益素领域也在蓬勃发展，它们将活性细菌与辅助纤维相结合。

本报告重点分析了美洲、欧洲、中东和非洲以及亚太地区的关键区域见解，揭示了地理趋势和成长催化剂。

全球微生物组产业在不同地区的采用率、法规结构和研发投入方面存在差异，从而塑造了不同的成长轨迹。在美洲，精准医疗的完善基础设施和领先的学术研究中心正在加速临床检验研究，尤其是在肠道和皮肤微生物组领域。北美地区创业投资和支持性监管政策的汇聚，正推动着专注于创新治疗方法和直接面向消费者的诊断服务的Start-Ups公司蓬勃发展。

分析塑造人类微生物组领域竞争动态的关键产业参与者的策略、合作关係和技术创新。

人类微生物组领域的竞争格局由众多参与者构成，既有老牌製药巨头，也有专注于特定领域的生物技术公司和敏捷的诊断设备创新者。现有医疗机构正透过收购微生物组疗法Start-Ups和与学术机构合作来拓展其产品线，并检验微生物组干预的新适应症。同时，早期公司也在建立策略伙伴关係，以加速临床开发并扩大其在代谢性疾病和感染疾病等特定治疗领域的市场份额。

我们提供切实可行的策略建议，帮助产业领导者优化投资、降低风险并最大限度地掌握新机会。

为了克服人类微生物组生态系统的复杂性并最大限度地提高创新投资回报，产业领导者应采取多管齐下的策略方法。首先，透过整合诊断、补充剂和治疗产品，实现产品系列多元化，可以减少对单一收入来源的依赖，并在临床和消费者管道中创造交叉销售机会。此外，透过与合约研究组织 (CRO) 和学术联盟建立合作关係，加速生物标记的发现和临床检验，可以进一步增强这种全面的市场定位。

提出调查方法，该方法结合了对专家的直接访谈、二手资料分析和高级分析框架，以确保获得可靠的见解。

本执行摘要的调查方法整合了多层次的资料收集和分析，以确保获得可靠且可操作的洞见。主要研究包括对高阶主管、学术意见领袖和临床医生进行深入访谈，以了解他们对技术进步、监管趋势和商业策略的第一手观点。此外，还辅以二手研究，包括对已发表文献、监管指导文件、行业白皮书和专利申请的全面审查。

本执行摘要概述了相关人员的关键趋势和未来发展方向，重申了策略重点，并提供了全面的人类微生物组的概述。

总之，充满活力的人类微生物组研究和商业化领域为诊断、治疗和健康应用提供了前所未有的创新机会。本概述阐明了微生物群落的基本作用，重点介绍了技术和政策方面的变革性变化，并分析了近期贸易关税对成本结构和供应链的影响。透过将这些研究结果与详细的市场区隔和区域框架结合，相关人员可以更好地调整其策略，使其更符合市场实际情况和患者需求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：人类微生物组市场：按类型划分

  • 抗生素
  • 诊断设备
    • 微生物组定序设备
    • 基于PCR的诊断
  • 益生元
    • 菊糖
    • 寡糖
  • 益生菌
  • 合益素

第九章：按微生物组分類的人类微生物组市场

  • 肠道微生物组
  • 鼻腔与呼吸道微生物组
  • 口腔微生物组
  • 皮肤微生物组
  • 阴道微生物组

第十章：人类微生物组市场：依应用领域划分

  • 诊断
    • 生物标记发现
    • 临床诊断
    • 伴随诊断
  • 补充
  • 治疗药物
    • 消化系统疾病
    • 感染疾病
    • 代谢性疾病
    • 皮肤病

第十一章 人类微生物组市场：依最终用户划分

  • 诊断检测实验室
  • 居家照护设施
  • 医院和诊所
  • 製药和生物技术公司
  • 研究机构

第十二章：人类微生物组市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：人类微生物组市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：人类微生物组市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国人类微生物组市场

第十六章：中国人类微生物组市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AOBiome, LLC
  • Axial Therapeutics, Inc.
  • BioHM Health Inc.
  • BiomeSense, Inc.
  • DuPont de Nemours, Inc.
  • Enterome Bioscience
  • Ferring BV
  • Finch Therapeutics Group, Inc.
  • Illumina, Inc.
  • Infinant Health Inc.
  • Intralytix, Inc.
  • Merck KGaA
  • Metabiomics Corporation
  • Osel Inc.
  • Pendulum Therapeutics
  • Synlogic, Inc.
  • Synthetic Biologics, Inc.
  • Viome Life Sciences, Inc.
  • Yakult Honsha Co., Ltd.
Product Code: MRR-430D42AA0FCD

The Human Microbiome Market was valued at USD 2.41 billion in 2025 and is projected to grow to USD 2.98 billion in 2026, with a CAGR of 24.83%, reaching USD 11.40 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.41 billion
Estimated Year [2026] USD 2.98 billion
Forecast Year [2032] USD 11.40 billion
CAGR (%) 24.83%

Uncovering the Human Microbiome Landscape Through a Comprehensive Introduction Highlighting Its Fundamental Roles, Historical Evolution, and Strategic Importance

The human microbiome has swiftly evolved from a niche scientific curiosity to a foundational element in understanding human health, disease prevention, and therapeutic innovation. This comprehensive introduction unpacks how the complex communities of microorganisms residing in and on the human body influence immune modulation, metabolic regulation, and neurological pathways. By examining seminal discoveries and key milestones in microbiome research, readers can appreciate the journey from early culture-based studies to high-throughput sequencing and multi-omics integrations.

Transitions within this field underscore the importance of interdisciplinary collaboration, as clinicians, microbiologists, bioinformaticians, and industry stakeholders converge to translate laboratory insights into real-world applications. This section establishes the essential context for the subsequent analysis by highlighting the microbiome's multifaceted role in diagnostics, supplements, and therapeutics. It sets the stage for exploring how foundational knowledge of microbial interactions is now driving precision medicine, personalized nutrition strategies, and novel drug discovery paradigms.

By grounding the executive summary in both historical perspective and contemporary relevance, this introduction ensures that decision-makers, investors, and research leaders gain a cohesive understanding of why the human microbiome continues to redefine the boundaries of healthcare innovation.

Identifying the Transformative Shifts Revolutionizing the Human Microbiome Landscape with Technological Breakthroughs Policy Advances and Strategic Collaborations

At the heart of the human microbiome's rapid evolution are transformative shifts fueled by cutting-edge technologies, policy reforms, and novel collaborative models. Recent advancements in sequencing technologies, including next-generation platforms and portable point-of-care devices, have drastically reduced turnaround times and costs, enabling real-time microbial profiling and fostering decentralized diagnostics.

Parallel to these technological breakthroughs, regulatory bodies have begun to establish clearer frameworks for microbiome-based products, particularly in the arenas of companion diagnostics and live biotherapeutic approvals. Evolving guidelines for clinical trials and quality assurance are streamlining pathways to market, incentivizing pharmaceutical and biotechnology entities to invest in pipeline expansion and strategic partnerships.

Equally impactful are cross-sector alliances that unite academic institutions, contract research organizations, and industry participants to co-develop standardized protocols for data sharing, analytical validation, and clinical applicability. These collaborations are redefining value chains, enabling stakeholders to transition from siloed research endeavors to integrated innovation ecosystems. Consequently, organizations that adapt to these shifts-by investing in agile methodologies, forging interdisciplinary alliances, and aligning with emergent regulations-are positioned to lead the next wave of microbiome discoveries.

Assessing the Cumulative Impact of 2025 United States Trade Tariffs on Supply Chains, Cost Structures, and Innovation Dynamics in Human Microbiome Sector

The implementation of United States trade tariffs in 2025 has introduced a complex array of challenges and strategic considerations for the human microbiome sector. Import duties on key inputs such as specialized reagents, high-precision sequencing instruments, and polymerase chain reaction components have exerted upward pressure on production costs for diagnostic devices and laboratory consumables. These cost inflations are prompting manufacturers to reevaluate supply chain configurations and consider localized sourcing or near-shoring strategies to mitigate exposure to tariff volatility.

Moreover, the cumulative effect of increased import duties has compelled stakeholders to scrutinize long-term partnerships with international suppliers, renegotiate contracts, and assess total landed costs for raw materials. In parallel, research and development budgets are being recalibrated to accommodate these additional expenses, which may impact the pace of innovation in areas such as live biotherapeutics, next-generation sequencing assays, and novel probiotic formulations.

Despite these headwinds, some organizations are leveraging tariff-driven disruption as an impetus for reshoring critical manufacturing processes and strengthening domestic supply resilience. By investing in local production of key reagents and equipment, companies can not only offset tariff burdens but also accelerate regulatory compliance timelines and reinforce quality control frameworks. Ultimately, the sector's ability to adapt procurement, production, and partnership strategies will determine how effectively it weathers the evolving trade landscape and sustains momentum in microbial research and commercialization.

Unveiling Critical Segmentation Insights by Type Target Microbiome Site Application and End User to Illuminate Diverse Market Dynamics

A granular understanding of market segmentation offers indispensable clarity into where growth opportunities and competitive pressures converge across the human microbiome value chain. By type, the market encompasses antibiotics, which continue to play a critical role in modulating microbial populations, as well as diagnostic devices that range from high-throughput microbiome sequencing platforms to rapid PCR-based assays. Meanwhile, the prebiotic category, anchored by inulin and oligosaccharides, underscores the importance of targeted substrates in nourishing beneficial microorganisms, complemented by the growing fields of probiotics and synbiotics that blend live cultures with supportive fibers.

Exploring the segmentation based on target microbiome site reveals distinct research and commercial pathways: the gut microbiome remains the largest focus of clinical and consumer interest, but substantial research initiatives now investigate nasal and respiratory, oral, skin, and vaginal microbial ecosystems. In parallel, application-based segmentation delineates three primary cohorts: diagnostics, which include early-stage biomarker discovery, clinical diagnostics, and companion diagnostic tools; supplements that range from functional foods to nutraceutical formulations; and therapeutics addressing gastrointestinal disorders, infectious diseases, metabolic syndromes, and dermatological conditions.

Lastly, end-user segmentation identifies diagnostic laboratories, home care settings, hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes as the principal conduits through which microbiome solutions reach the market. Together, these layered perspectives illuminate the nuanced interplay between scientific innovation, clinical utility, and commercial viability within the dynamic microbiome ecosystem.

Highlighting Key Regional Insights across the Americas Europe Middle East and Africa and Asia Pacific to Illuminate Geographic Trends and Growth Catalysts

Regional nuances in adoption, regulatory frameworks, and research investments have created differentiated trajectories for growth across the global microbiome landscape. In the Americas, robust infrastructure in precision medicine and the presence of leading academic centers have accelerated clinical validation studies, particularly in the gut and skin microbiome domains. The convergence of venture capital investment and supportive regulatory guidance in North America has catalyzed a surge of startup activity focused on innovative therapeutics and direct-to-consumer diagnostic offerings.

Turning to Europe, the Middle East, and Africa, a mosaic of regulatory harmonization efforts and collaborative initiatives between public research institutions and private firms is fostering a fertile environment for microbiome research. Policymakers across the European Union are advancing frameworks for live biotherapeutic products, while Middle Eastern markets are exploring strategic partnerships to integrate microbiome technologies into national health programs. Meanwhile, select African research consortia are leveraging microbial diversity studies to address endemic health challenges and unlock novel bioactive compounds.

In the Asia-Pacific region, rapid digital health adoption, expansive population cohorts, and growing healthcare expenditures are fueling interest in both therapeutic interventions and functional foods designed to optimize microbial health. Governments and industry players are forging consortia to drive large-scale population studies, while regional manufacturers are scaling up production of prebiotic and probiotic formulations to serve local and export markets. These regional insights underscore the importance of tailored strategies that align with unique regulatory, clinical, and consumer contexts.

Analyzing Leading Industry Participants Strategies Collaborations and Technological Innovations Shaping Competitive Dynamics within the Human Microbiome

The competitive landscape of the human microbiome sector is defined by a diverse array of actors, ranging from established pharmaceutical giants to specialized biotechnology firms and agile diagnostic device innovators. Legacy healthcare organizations are expanding their pipelines through acquisitions of microbial therapeutics startups and collaborations with academic centers to validate novel indications for microbiome interventions. Concurrently, early-stage firms are securing strategic partnerships to accelerate clinical development and gain traction in target therapeutic areas such as metabolic disorders and infectious diseases.

Diagnostic device manufacturers, leveraging capabilities in high-throughput sequencing and PCR-based platforms, are investing in integrated solutions that combine sample-to-result workflows with advanced bioinformatics analytics. These endeavors are supported by contract research organizations that specialize in microbial assay validation and regulatory consulting, creating an ecosystem that facilitates faster market entry and quality compliance.

Supplement providers and nutraceutical companies are differentiating through proprietary formulations of prebiotics, probiotics, and synbiotics, often backed by human clinical trials and consumer wellness studies. This convergence of scientific rigor and consumer engagement is intensifying competition in the direct-to-consumer segment, compelling players to invest in digital health tools and personalized nutrition platforms. Collectively, the strategic maneuvers of these companies-spanning mergers, licensing agreements, and co-development programs-are reshaping the contours of competitive advantage within the microbiome arena.

Delivering Actionable Strategic Recommendations to Empower Industry Leaders Optimize Investments Mitigate Risks and Capitalize on Emerging Opportunities

To navigate the complexities of the human microbiome ecosystem and maximize return on innovation investments, industry leaders should pursue a multi-pronged strategic approach. First, diversifying product portfolios by integrating diagnostics, supplements, and therapeutics will reduce reliance on any single revenue stream and enable cross-selling opportunities across clinical and consumer channels. This holistic positioning can be further strengthened by forging alliances with contract research organizations and academic consortia to accelerate biomarker discovery and clinical validation.

Second, investing in regional manufacturing footprints and supply chain resilience is critical in light of evolving trade policies and input cost fluctuations. Establishing localized reagent production and scalable fermentation capabilities will safeguard against external disruptions while optimizing total cost of ownership and regulatory compliance timelines.

Third, adopting advanced analytical frameworks, including machine learning-driven microbial signature analysis and digital health integrations, will empower real-time decision-making and personalized treatment protocols. Combining these capabilities with patient engagement platforms enhances data collection and outcomes monitoring, fostering long-term value generation.

Finally, proactive engagement with regulatory stakeholders and participation in industry standardization initiatives will streamline approval pathways and bolster stakeholder confidence. By championing best practices for quality assurance and data transparency, organizations can solidify their reputations as trusted partners in the evolving human microbiome field.

Presenting a Research Methodology Combining Primary Expert Interviews Secondary Data Analysis and Advanced Analytical Frameworks to Ensure Robust Insights

The research methodology underpinning this executive summary integrates multiple layers of data collection and analysis to ensure robust, actionable insights. Primary research involved in-depth interviews with senior executives, academic thought leaders, and clinical practitioners to capture firsthand perspectives on technological advancements, regulatory trends, and commercial strategies. These qualitative inputs were complemented by secondary research, which encompassed a comprehensive review of published literature, regulatory guidance documents, industry white papers, and patent filings.

Data triangulation techniques were employed to validate emerging trends and reconcile discrepancies between conflicting data points. Advanced analytical frameworks, including cluster analysis of segmentation variables and scenario planning around trade tariff impacts, were applied to deepen the understanding of market dynamics. Comparative analyses across geographic regions and end-user categories further enriched the contextual narrative, enabling a balanced assessment of growth drivers and potential inhibitors.

Finally, an expert validation process engaged a panel of multidisciplinary advisors to review key findings, verify assumptions, and refine strategic recommendations. This rigorous, multi-stage approach ensures that the insights presented herein are grounded in empirical evidence and reflect the latest developments within the human microbiome landscape.

Summarizing the Comprehensive Human Microbiome Executive Summary to Reinforce Strategic Takeaways Critical Trends and the Path Forward for Stakeholders

In conclusion, the dynamic field of human microbiome research and commercialization offers unprecedented opportunities for innovation across diagnostics, therapeutics, and wellness applications. This summary has illuminated the foundational roles of microbial communities, highlighted transformative shifts in technology and policy, and dissected the implications of recent trade tariffs on cost structures and supply chains. By contextualizing these findings within detailed segmentation and regional frameworks, stakeholders can better align their strategies with market realities and patient needs.

The competitive landscape is being reshaped by strategic partnerships, mergers, and technological integrations that drive differentiation and accelerate time to market. Forward-thinking organizations that embrace diversified portfolios, invest in supply chain resilience, and leverage advanced analytics will be poised to lead the next wave of microbiome breakthroughs.

As this sector continues to evolve, ongoing collaboration between industry, academia, and regulatory authorities will be critical to translating scientific discovery into tangible health outcomes. The pathways outlined in this executive summary offer a strategic blueprint for navigating complexity and capitalizing on the transformative potential of the human microbiome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Microbiome Market, by Type

  • 8.1. Antibiotics
  • 8.2. Diagnostic Devices
    • 8.2.1. Microbiome Sequencing Devices
    • 8.2.2. PCR-Based Diagnostics
  • 8.3. Prebiotics
    • 8.3.1. Inulin
    • 8.3.2. Oligosaccharides
  • 8.4. Probiotics
  • 8.5. Synbiotics

9. Human Microbiome Market, by Target Microbiome Site

  • 9.1. Gut Microbiome
  • 9.2. Nasal & Respiratory Microbiome
  • 9.3. Oral Microbiome
  • 9.4. Skin Microbiome
  • 9.5. Vaginal Microbiome

10. Human Microbiome Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Biomarker Discovery
    • 10.1.2. Clinical Diagnostics
    • 10.1.3. Companion Diagnostics
  • 10.2. Supplements
  • 10.3. Therapeutics
    • 10.3.1. Gastrointestinal Disorders
    • 10.3.2. Infections
    • 10.3.3. Metabolic Disorders
    • 10.3.4. Skin Disorders

11. Human Microbiome Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Home Care Settings
  • 11.3. Hospitals & Clinics
  • 11.4. Pharmaceutical & Biotechnology Companies
  • 11.5. Research Institutes

12. Human Microbiome Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Microbiome Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Microbiome Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Human Microbiome Market

16. China Human Microbiome Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AOBiome, LLC
  • 17.6. Axial Therapeutics, Inc.
  • 17.7. BioHM Health Inc.
  • 17.8. BiomeSense, Inc.
  • 17.9. DuPont de Nemours, Inc.
  • 17.10. Enterome Bioscience
  • 17.11. Ferring B.V.
  • 17.12. Finch Therapeutics Group, Inc.
  • 17.13. Illumina, Inc.
  • 17.14. Infinant Health Inc.
  • 17.15. Intralytix, Inc.
  • 17.16. Merck KGaA
  • 17.17. Metabiomics Corporation
  • 17.18. Osel Inc.
  • 17.19. Pendulum Therapeutics
  • 17.20. Synlogic, Inc.
  • 17.21. Synthetic Biologics, Inc.
  • 17.22. Viome Life Sciences, Inc.
  • 17.23. Yakult Honsha Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY MICROBIOME SEQUENCING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY MICROBIOME SEQUENCING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY MICROBIOME SEQUENCING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PCR-BASED DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PCR-BASED DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PCR-BASED DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OLIGOSACCHARIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OLIGOSACCHARIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OLIGOSACCHARIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SYNBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SYNBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SYNBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GUT MICROBIOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GUT MICROBIOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GUT MICROBIOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY NASAL & RESPIRATORY MICROBIOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY NASAL & RESPIRATORY MICROBIOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY NASAL & RESPIRATORY MICROBIOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ORAL MICROBIOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ORAL MICROBIOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ORAL MICROBIOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN MICROBIOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN MICROBIOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN MICROBIOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY VAGINAL MICROBIOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY VAGINAL MICROBIOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY VAGINAL MICROBIOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 183. GCC HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 184. GCC HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. G7 HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 210. G7 HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. NATO HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 224. NATO HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)